Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Identifieur interne : 000143 ( PubMed/Checkpoint ); précédent : 000142; suivant : 000144Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Auteurs : Matthieu F. Bastide [France] ; Brice De La Crompe [France] ; Evelyne Doudnikoff [France] ; Pierre-Olivier Fernagut [France] ; Christian E. Gross [France] ; Nicolas Mallet [France] ; Thomas Boraud [France] ; Erwan Bézard [France]Source :
- Biological psychiatry [ 1873-2402 ] ; 2016.
English descriptors
- KwdEn :
- Animals, Corpus Striatum (drug effects), Daunorubicin (administration & dosage), Daunorubicin (analogs & derivatives), Deoxyglucose (pharmacokinetics), Disease Models, Animal, Dyskinesia, Drug-Induced (drug therapy), Electrophysiology, Female, Genes, Immediate-Early, Habenula (drug effects), Levodopa (adverse effects), Macaca fascicularis, Male, Oxidopamine (administration & dosage), Parkinson Disease (complications), Rats, Rats, Sprague-Dawley.
- MESH :
- chemical , administration & dosage : Daunorubicin, Oxidopamine.
- chemical , adverse effects : Levodopa.
- chemical , analogs & derivatives : Daunorubicin.
- complications : Parkinson Disease.
- drug effects : Corpus Striatum, Habenula.
- drug therapy : Dyskinesia, Drug-Induced.
- chemical , pharmacokinetics : Deoxyglucose.
- Animals, Disease Models, Animal, Electrophysiology, Female, Genes, Immediate-Early, Macaca fascicularis, Male, Rats, Rats, Sprague-Dawley.
Abstract
A systematic search of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in Parkinson's disease shed light, notably, upon the lateral habenula (LHb), which displayed an overexpression of the ∆FosB, ARC, and Zif268 immediate-early genes only in rats experiencing abnormal involuntary movements (AIMs). We thus hypothesized that LHb might play a role in LID.
DOI: 10.1016/j.biopsych.2014.08.022
PubMed: 25442003
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25442003Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.</title><author><name sortKey="Bastide, Matthieu F" sort="Bastide, Matthieu F" uniqKey="Bastide M" first="Matthieu F" last="Bastide">Matthieu F. Bastide</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="De La Crompe, Brice" sort="De La Crompe, Brice" uniqKey="De La Crompe B" first="Brice" last="De La Crompe">Brice De La Crompe</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Doudnikoff, Evelyne" sort="Doudnikoff, Evelyne" uniqKey="Doudnikoff E" first="Evelyne" last="Doudnikoff">Evelyne Doudnikoff</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Gross, Christian E" sort="Gross, Christian E" uniqKey="Gross C" first="Christian E" last="Gross">Christian E. Gross</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France; Centre Hospitalier Universitaire de Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Mallet, Nicolas" sort="Mallet, Nicolas" uniqKey="Mallet N" first="Nicolas" last="Mallet">Nicolas Mallet</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Boraud, Thomas" sort="Boraud, Thomas" uniqKey="Boraud T" first="Thomas" last="Boraud">Thomas Boraud</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bézard">Erwan Bézard</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France. Electronic address: erwan.bezard@u-bordeaux.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:25442003</idno><idno type="pmid">25442003</idno><idno type="doi">10.1016/j.biopsych.2014.08.022</idno><idno type="wicri:Area/PubMed/Corpus">000178</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000178</idno><idno type="wicri:Area/PubMed/Curation">000178</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000178</idno><idno type="wicri:Area/PubMed/Checkpoint">000178</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000178</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.</title><author><name sortKey="Bastide, Matthieu F" sort="Bastide, Matthieu F" uniqKey="Bastide M" first="Matthieu F" last="Bastide">Matthieu F. Bastide</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="De La Crompe, Brice" sort="De La Crompe, Brice" uniqKey="De La Crompe B" first="Brice" last="De La Crompe">Brice De La Crompe</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Doudnikoff, Evelyne" sort="Doudnikoff, Evelyne" uniqKey="Doudnikoff E" first="Evelyne" last="Doudnikoff">Evelyne Doudnikoff</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Gross, Christian E" sort="Gross, Christian E" uniqKey="Gross C" first="Christian E" last="Gross">Christian E. Gross</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France; Centre Hospitalier Universitaire de Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Mallet, Nicolas" sort="Mallet, Nicolas" uniqKey="Mallet N" first="Nicolas" last="Mallet">Nicolas Mallet</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Boraud, Thomas" sort="Boraud, Thomas" uniqKey="Boraud T" first="Thomas" last="Boraud">Thomas Boraud</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bézard">Erwan Bézard</name><affiliation wicri:level="4"><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France. Electronic address: erwan.bezard@u-bordeaux.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author></analytic><series><title level="j">Biological psychiatry</title><idno type="eISSN">1873-2402</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Corpus Striatum (drug effects)</term><term>Daunorubicin (administration & dosage)</term><term>Daunorubicin (analogs & derivatives)</term><term>Deoxyglucose (pharmacokinetics)</term><term>Disease Models, Animal</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Electrophysiology</term><term>Female</term><term>Genes, Immediate-Early</term><term>Habenula (drug effects)</term><term>Levodopa (adverse effects)</term><term>Macaca fascicularis</term><term>Male</term><term>Oxidopamine (administration & dosage)</term><term>Parkinson Disease (complications)</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Daunorubicin</term><term>Oxidopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Daunorubicin</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Habenula</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Deoxyglucose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Electrophysiology</term><term>Female</term><term>Genes, Immediate-Early</term><term>Macaca fascicularis</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A systematic search of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in Parkinson's disease shed light, notably, upon the lateral habenula (LHb), which displayed an overexpression of the ∆FosB, ARC, and Zif268 immediate-early genes only in rats experiencing abnormal involuntary movements (AIMs). We thus hypothesized that LHb might play a role in LID.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25442003</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>05</Day></DateCreated><DateCompleted><Year>2016</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol. Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.</ArticleTitle><Pagination><MedlinePgn>345-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2014.08.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-3223(14)00674-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A systematic search of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in Parkinson's disease shed light, notably, upon the lateral habenula (LHb), which displayed an overexpression of the ∆FosB, ARC, and Zif268 immediate-early genes only in rats experiencing abnormal involuntary movements (AIMs). We thus hypothesized that LHb might play a role in LID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">∆FosB immunoreactivity, 2-deoxyglucose uptake, and firing activity of LHb were studied in experimental models of Parkinson's disease and LID. ΔFosB-expressing LHb neurons were then targeted using the Daun02-inactivation method. A total of 18 monkeys and 55 rats were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">LHb was found to be metabolically modified in dyskinetic monkeys and its neuronal firing frequency significantly increased in ON L-DOPA dyskinetic 6-hydroxydopamine-lesioned rats, suggesting that increased LHb neuronal activity in response to L-DOPA is related to AIM manifestation. Therefore, to mechanistically test if LHb neuronal activity might affect AIM severity, following induction of AIMs, 6-hydroxydopamine rats were injected with Daun02 in the LHb previously transfected with ß-galactosidase under control of the FosB promoter. Three days after Daun02 administration, animals were tested daily with L-DOPA to assess LID and L-DOPA-induced rotations. Inactivation of ∆FosB-expressing neurons significantly reduced AIM severity and also increased rotations. Interestingly, the dopaminergic D1 receptor was overexpressed only on the lesioned side of dyskinetic rats in LHb and co-localized with ΔFosB, suggesting a D1 receptor-mediated mechanism supporting the LHb involvement in AIMs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study highlights the role of LHb in LID, offering a new target to innovative treatments of LID.</AbstractText><CopyrightInformation>Copyright © 2016. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bastide</LastName><ForeName>Matthieu F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Crompe</LastName><ForeName>Brice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doudnikoff</LastName><ForeName>Evelyne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernagut</LastName><ForeName>Pierre-Olivier</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Christian E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallet</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boraud</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bézard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France; National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France. Electronic address: erwan.bezard@u-bordeaux.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C576267">N-(4''-(galactopyranosyl)-3''-nitrobenzyloxycarbonyl)daunomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9G2MP84A8W</RegistryNumber><NameOfSubstance UI="D003847">Deoxyglucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZS7284E0ZP</RegistryNumber><NameOfSubstance UI="D003630">Daunorubicin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003630" MajorTopicYN="N">Daunorubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003847" MajorTopicYN="N">Deoxyglucose</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017781" MajorTopicYN="N">Genes, Immediate-Early</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019262" MajorTopicYN="N">Habenula</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2-Deoxyglucose</Keyword><Keyword MajorTopicYN="N">Daun02</Keyword><Keyword MajorTopicYN="N">Electrophysiology</Keyword><Keyword MajorTopicYN="N">Macaque</Keyword><Keyword MajorTopicYN="N">Parkinson’s disease</Keyword><Keyword MajorTopicYN="N">Rat</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>08</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25442003</ArticleId><ArticleId IdType="pii">S0006-3223(14)00674-X</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2014.08.022</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement><orgName><li>Université de Bordeaux</li></orgName></list><tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Bastide, Matthieu F" sort="Bastide, Matthieu F" uniqKey="Bastide M" first="Matthieu F" last="Bastide">Matthieu F. Bastide</name></region><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bézard">Erwan Bézard</name><name sortKey="Boraud, Thomas" sort="Boraud, Thomas" uniqKey="Boraud T" first="Thomas" last="Boraud">Thomas Boraud</name><name sortKey="De La Crompe, Brice" sort="De La Crompe, Brice" uniqKey="De La Crompe B" first="Brice" last="De La Crompe">Brice De La Crompe</name><name sortKey="Doudnikoff, Evelyne" sort="Doudnikoff, Evelyne" uniqKey="Doudnikoff E" first="Evelyne" last="Doudnikoff">Evelyne Doudnikoff</name><name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name><name sortKey="Gross, Christian E" sort="Gross, Christian E" uniqKey="Gross C" first="Christian E" last="Gross">Christian E. Gross</name><name sortKey="Mallet, Nicolas" sort="Mallet, Nicolas" uniqKey="Mallet N" first="Nicolas" last="Mallet">Nicolas Mallet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000143 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000143 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25442003
|texte= Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25442003" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |